M. Fontenay No disclosure
T. Ganz Not received
M. Ghashghaeinia No disclosure
O. Hermine Not received
D. Higgs Cellinta
Sangamo
Scientific Advisory Board
Scientific Advisory Board
A. Iolascon No disclosure
J. Irish
S. Kordasti Not received
G. Liumbruno No disclosure
A. Mekinian
I. Motta Sanofi Genzyme
Amicus Therapeutics
Speakers’ bureau, Scientific Advisory Board
Scientific Advisory Board
M. Muckentaler Novartis Pharma Coop
Incyte Biosciences
Germany GmbH
Merck Selbstmedikation
GmbH
Vifor Pharma Ltd.
Silence Therapeutics PLC
Consultant (2015), Scientific Advisory Board (2020)
Scientific Advisory Board (2020)
Other (2017)
Scientific Advisory Board (2016)
Consultant (2016)
M. Narla
S. Orkin No disclosure
A. Piga Not received
U. Platzbecker Not received
J. Porter Not received
G. Porto Not received
M. Raaijmakers No disclosure
R. Russo No disclosure
V. Sankaran Vertex Pharmaceuticals Research support
V. Santini Celgene/BMS
Takeda
Geron
Novartis
Menarini
Research support, Consultant, Scientific Advisory
Board
Consultant, Scientific Advisory Board
Consultant, Scientific Advisory Board
Research support, Scientific Advisory Board
Consultant, Scientific Advisory Board
SCIENTIFIC PROGRAMME
SESSION I
BONE MARROW
RESPONSE TO VIRAL
INFECTIONS
SESSION II
HAEMATOLOGICAL
RESPONSE TO SARS
COV2 INFECTION
SESSION III
DYSERYTHROPOIESIS IN
CLONAL HAEMOPOIESIS
AND MDS
SESSION IV
ERYTHROPOIESIS
CONTROL
SESSION V
ERYTHROPOIESIS
CONTROL : PHASE 2
SESSION VI
IRON METABOLISM
AND ERYTHROPOIESIS
SESSION VII
INHERITED
DYSERYTHROPOIESIS
SESSION VIII
GENE THERAPY/EDITION
SESSION IX – DRUGS
AND INEFFECTIVE
ERYTHROPOIESIS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES